The recall includes a range of … (2020, June 15). Metformin 02380196.
Health Canada has shared a list of the affected lots on its website. Company test results showed one of the lots (PY7174) contains a nitrosamine impurity called N-nitrosodimethylamine (NDMA) that increased over time to a level above the acceptable limit. All Rights Reserved. Simply enter your e-mail address and click on the "Sign me up!" This is an update to a previous statement regarding a recall of metformin tablets in Canada.. As a result of its recent product analysis, Ranbaxy Pharmaceuticals Canada Inc. is recalling six lots of its prescription RAN-Metformin drug from the Canadian market due to findings of nitrosamine impurity called N-nitrosodimethylamine (NDMA). Five drug companies told to recall diabetes medication amid cancer fears .

APO-Metformin (2020-06-12) Report a Concern. June 05, 2020 -- Apotex is expanding the previously announced Retail Level recall of Metformin Hydrochloride Extended-Release Tablets, USP 500mg that was initiated on May 29, 2020 to Consumer Level. “We understand this news may be unsettling for all those who rely on metformin to manage their condition,” says Seema Nagpal, vice-president of Science & Policy with Diabetes Canada. NDMA is not expected to cause harm when ingested at low levels. Please refer to the Affected products table below for detailed information on the recalled lots. Apotex Inc. has tested all lots of its 500 mg extended release tablets; only the affected lots are being recalled (see table below). A person taking a drug that contains NDMA at or below the acceptable level every day for 70 years is not expected to have an increased risk of cancer.“We understand there are more companies currently testing their metformin products that have yet to provide their results and we urge Health Canada to expedite this process,” says Nagpal.Diabetes Canada will continue to provide updates through our newsroom and social media channels. Apotex Inc. is voluntarily recalling nine additional lots of its prescription metformin drug, APO-METFORMIN ER (extended release) 500mg tablets. This is an update to a previous statement regarding a recall of metformin tablets in Canada. This image made available by the U.S. Food and Drug Administration on Thursday, May 28, 2020 shows a label for the drug metformin. X20284. FDA Asks Companies to Recall Diabetes Medication Metformin Over Cancer-Causing Chemical Written by Julia Ries on June 3, 2020 — Fact checked by Dana K. Cassell Ranbaxy Pharmaceuticals Canada Inc. is recalling six lots of its prescription RAN-Metformin drug from the Canadian market. Patients who are taking an affected metformin drug. There are also alternative Metformin products on the Canadian market manufactured by other companies.==> Never depend on your senses of sight, smell, taste or touch to confirm drug poisoning or contamination.Please talk to your physician or other qualified health care provider to discuss treatment options if you are taking a recalled product or if you have taken a recalled product and are concerned about your health.Disposal of this product must be in accordance with local municipal hazardous waste requirements to protect your personal safety, the local drinking water supply and the ecosystem.If you have any further questions, comments or complaints about this recall, please contact Apotex Inc. via Stericycle ULC by calling toll-free at 1-855-853-9461 during normal business hours Eastern Standard Time, Monday to Friday.Please note: the Canada Consumer Product Safety Act prohibits recalled products from being redistributed, sold or even given away in Canada.==> To see other recalls and notifications caused by suspected contaminated, adulterated or mislabeled Metformin, please search for “Metformin” using the Search Box at the top of this page.==> To see all recalls and notifications relating to Carcinogen hazards, please search for “Cancer” using the Search Box at the top of this page.==> To see all recalls and notifications relating to Infants and Children, please search for “children” using the Search Box at the top of this page.==> To see other recalls and notifications for products manufactured, marketed and/or sold by Apotex Inc., please search for “Apotex” using the Search Box at the top of this page.Under US law it's illegal for any person or entity to sell recalled foods, products or vehicles. Starting date: June 12, 2020 Type of communication: Drug Recall Subcategory: Drugs Hazard classification: Type I Source of recall: Health Canada Issue: Product Safety Audience: General Public, Healthcare Professionals, Hospitals Identification number: RA-73339 . ... 05/2020. Apotex recalls some Metformin batches due to possible carcinogen. All Rights Reserved. Should any additional recalls be necessary, Health Canada will update the table below and inform Canadians. NDMA is classified as a probable human carcinogen. After product testing, two lots (#AJY8006A and #AJY8007A) had NDMA levels above what is considered acceptable if the drug were to be taken over a lifetime. The Metformin was packaged under the Actavis Pharma label and was distributed nationwide from Jan. 8, 2019 to May 27, 2020.

button to receive notifications of new recalls automatically!According to Health Canada, Apotex has recalled eight (8) lots of its 500 mg Extended Release Metformin tablets (“APO-Metformin ER”) because they contain a Nitrosamine impurity called N-nitrosodimethylamine (“NDMA”) above the acceptable limit. We are all exposed to low levels of nitrosamines through a variety of foods (such as smoked and cured meats, dairy products and vegetables), drinking water and air pollution. Canada/Ottawa: Apotex Inc., a Toronto, Ontario establishment, recalls certain batch/lots of the APO-Metformin ER Diabetes medication from the Canadian marketplace due to levels of Nitrosamines ("NDMA") in excess of Canadian health regulations and consequential long-term risk of certain forms of Cancer, all serious health and safety hazards. NDMA test results are not available for this product; this recall has been initiated because of the potential presence of nitrosamine impurities in the finished product. APO-Metformin (2020-02-04) Report a Concern.

You should not stop taking your medication without first discussing treatment options with your health care provider.